NovoCure Files 8-K: Corporate Updates and Financials
Ticker: NVCR · Form: 8-K · Filed: Sep 15, 2025 · CIK: 1645113
| Field | Detail |
|---|---|
| Company | Novocure Ltd (NVCR) |
| Form Type | 8-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, financial-reporting, regulatory-disclosure
Related Tickers: NVCR
TL;DR
NovoCure 8-K filed Sept 15, 2025 - corporate details and financials updated.
AI Summary
NovoCure Limited filed an 8-K on September 15, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF, with a business phone number of +44 (0) 15 3475 6700. The company was formerly known as Novocure Ltd, with a name change effective June 15, 2015.
Why It Matters
This 8-K filing provides essential corporate information and regulatory disclosures for NovoCure Limited, impacting investors' understanding of the company's operational and financial reporting status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- NovoCure Limited (company) — Registrant
- Novocure Ltd (company) — Former company name
- September 15, 2025 (date) — Date of Report
- No. 4 The Forum, Grenville Street St. Helier Jersey JE2 4UF (address) — Principal Executive Offices
- +44 (0) 15 3475 6700 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for NovoCure Limited?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits as of September 15, 2025.
When was the name change for NovoCure Limited effective?
The name change for NovoCure Limited (formerly Novocure Ltd) was effective on June 15, 2015.
Where are NovoCure Limited's principal executive offices located?
NovoCure Limited's principal executive offices are located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF.
What is the telephone number provided for NovoCure Limited?
The telephone number provided for NovoCure Limited is +44 (0) 15 3475 6700.
What is the SEC file number for NovoCure Limited?
The SEC file number for NovoCure Limited is 001-37565.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-09-15 07:00:10
Filing Documents
- nvcr-20250915.htm (8-K) — 24KB
- nsclcjapanapprovalpr.htm (EX-99.1) — 18KB
- 0001645113-25-000037.txt ( ) — 162KB
- nvcr-20250915.xsd (EX-101.SCH) — 2KB
- nvcr-20250915_lab.xml (EX-101.LAB) — 21KB
- nvcr-20250915_pre.xml (EX-101.PRE) — 12KB
- nvcr-20250915_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 15, 2025, the Company issued a press release announcing that that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. The information contained in this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated September 15, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: September 15, 2025 By: /s/ Christoph Brackmann Name: Christoph Brackmann Title: Chief Financial Officer